| ［1］ |
Williams KA, Huang AH, Belzberg M, et al. Prurigo nodularis: pathogenesis and management［J］. J Am Acad Dermatol, 2020,83（6）:1567⁃1575. doi: 10.1016/j.jaad.2020.04.182.
|
| ［2］ |
Bonecchi R, Facchetti F, Dusi S, et al. Induction of functional IL⁃8 receptors by IL⁃4 and IL⁃13 in human monocytes［J］. J Immunol, 2000,164（7）:3862⁃3869. doi: 10.4049/jimmunol.164. 7.3862.
|
| ［3］ |
Calugareanu A, Jachiet M, Tauber M, et al. Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients［J］. J Eur Acad Dermatol Venereol, 2020,34（2）:e74⁃e76. doi: 10.1111/jdv.15957.
|
| ［4］ |
Beck KM, Yang EJ, Sekhon S, et al. Dupilumab treatment for generalized prurigo nodularis［J］. JAMA Dermatol, 2019,155（1）:118⁃120. doi: 10.1001/jamadermatol.2018.3912.
|
| ［5］ |
Almustafa ZZ, Weller K, Autenrieth J, et al. Dupilumab in treatment of chronic prurigo: a case series and literature review［J］. Acta Derm Venereol, 2019,99（10）:905⁃906. doi: 10. 2340/00015555⁃3243.
|
| ［6］ |
陈佳雯, 张谊华, 彭佳美, 等. 度普利尤单抗治疗结节性痒疹四例报告［J］. 中华临床免疫和变态反应杂志, 2021,15（5）:546⁃548. doi: 10.3969∕j.issn.1673⁃8705.2021.05.010.
|
